Long-term comparative efficacy of cyclosporine- or infliximab-based strategies for the management of steroid-refractory ulcerative colitis attacks

Juan E. Naves, Jordina Llaó, Alexandra Ruiz-Cerulla, Cristina Romero, Míriam Mañosa, Triana Lobatón, Eduard Cabré, Esther Garcia-Planella, Jordi Guardiola, Eugeni Domènech

Research output: Contribution to journalArticleResearchpeer-review

18 Citations (Scopus)

Abstract

Background: The short-term efficacy of infliximab (IFX) and cyclosporine A (CsA) in steroid-refractory ulcerative colitis (SRUC) has been recently shown to be similar, but long-term outcomes are still unclear. Moreover, the need for further rescue therapies in patients treated with IFX or CsA for SRUC has not been reported. The aims of our study were to compare short-term and long-term efficacy between 2 different strategies based on initial treatment with CsA or IFX for SRUC attacks. Patients and Methods: Between January 2005 and December 2011, all patients admitted for SRUC who required medical rescue therapy were identified from the electronic databases of 3 referral centers and grouped according to whether they received CsA or IFX as first-line rescue therapy, and retrospectively reviewed. Results: Among 50 SRUC attacks, 20 were treated with CsA as first-line rescue therapy and 30 with IFX. The CsA group had a higher proportion of patients with severe UC activity immediately before rescue therapy (P = 0.03) and a shorter median time from intravenous corticosteroids to rescue therapy (P = 0.03). A higher proportion of patients in the CsA group received second-line drug therapy (switch) as compared with the IFX group (P = 0.04). Fifteen patients (30%) were colectomized during the study period, with no between-group differences. Previous thiopurine exposure (P = 0.004; odds ratio = 6.1 [1.7-20.9]) was the only independent predictor of colectomy. Conclusions: CsA- and IFX-based strategies for SRUC seem similarly effective in preventing colectomy in the short and long term, although secondline drug therapy is more often required with CsA-based strategies. Copyright © 2014 Crohn's & Colitis Foundation of America, Inc.
Original languageEnglish
Pages (from-to)1375-1381
JournalInflammatory Bowel Diseases
Volume20
Issue number8
DOIs
Publication statusPublished - 1 Jan 2014

Keywords

  • Colectomy
  • Cyclosporine
  • Infliximab
  • Refractoriness
  • Ulcerative colitis

Fingerprint Dive into the research topics of 'Long-term comparative efficacy of cyclosporine- or infliximab-based strategies for the management of steroid-refractory ulcerative colitis attacks'. Together they form a unique fingerprint.

Cite this